Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
NCT07695701
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
- Amyloidosis
- Amyloid Cardiomyopathy
- Transthyretin Amyloidosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eidos Therapeutics, a BridgeBio company
- Last updated on ClinicalTrials.gov
- July 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Missouri · 1
- Washington University in St. Louis · St Louis, MO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.